Antonio Giovanni Solimando, MD
graduated from Bari Medical School University, Italy, in 2011 (Magna cum Laude) and is a resident doctor in internal medicine since 2012. He has been active in both, clinical and pre-clinical translational research activities at the Internal Medicine Unit, Department of Biomedical Sciences and Human Oncology at Bari Medical School University. Focusing on the field of hematology he investigates the interactions of multiple myeloma and the tumor microenvironment. In October 2014 he started an international fellowship in the Department of Medicine II at Würzburg University Hospital and joined the Experimental Stem Cell Laboratory to investigate dynamic interactions of malignant plasma cells with the bone marrow niche environment in preclinical models. To gain better insights into these complex processes he employs state-of-the-art imaging techniques to ultimately translate his findings into improved diagnostics and therapies.
Dr. Antonio Solimando
Tel: +49-931-201 27637 or
Tel: +49-931-201 44155
Young Investigator’s Award of the German, Austrian and Swiss Societies of Hematology and Oncology, September 28-October 3, 2018, Vienna, Austria
ASH Abstract Achievement Award, 58th American Society of Hematology (ASH) Conference from December 3-6, 2016 in San Diego, CA.
Special Mention by the Committee for the great ability demonstrated as investigator of significantly scientific production; Bari Medical Board’s Research Reward 2014. Bari (Italy) May 21, 2014.
Best Oral communication: Solimando AG, Di Marzo L, Rao L, Ria R, Berardi S, Catacchio I, Vacca A, Frassanito MA. Proangiogenic effect of Bone marrow fibroblasts in patients with multiple myeloma. SIMI National Meeting, Rome (Italy) October 26-28, 2013.
Solimando AG, Da Vià MC, Cicco S, Leone P, Di Lernia G, Giannico D, Desantis V, Frassanito MA, Morizio A, Delgado Tascon J, Ranieri G, Ria R, Rasche L, Kortüm KM, Beilhack A, Racanelli V, Vacca A*, Einsele H*. (2019). High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment. J Clin Med 8(7): 997
Solimando AG*, Brandl A*, Mattenheimer K, Graf C, Ritz M, Ruckdeschel A, Stühmer T, Mokhtari Z, Rudelius M, Dotterweich J, Bittrich M, Desanti V, Ebert R, Trerotoli P, Frassanito MA, Rosenwald A, Vacca A, Einsele H, Jakob F, Beilhack A. (2017). JAM-A as a prognostic factor and new therapeutic target in multiple myeloma. Leukemia 32(3):736-743. (*contributed equally)
Rudelius M, Rosenfeldt MT, Leich E, Rauert-Wunderlich H, Solimando AG, Beilhack A, Ott G, Rosenwald A. (2017). Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow micro-environment. Haematologica [Epub ahead of print] doi: 10.3324/haematol.2017.177162.
Solimando AG, Ribatti D, Vacca A, Einsele H. (2016). Targeting B-cell non Hodgkin lymphoma: New and old tricks (Review). Leukemia Research 42:93-104.
Moschetta M, Basile A, Ferrucci A, Frassanito MA, Rao L, Ria R, Solimando AG, Giuliani N, Boccarelli A, Fumarola F, Coluccia M, Rossini B, Ruggieri S, Nico B, Maiorano E, Ribatti D, Roccaro AM, Vacca A. (2013). Novel targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myeloma. Clin Cancer Res. 19(16):4371-4382.
Ferrucci A, Moschetta M, Frassanito MA, Berardi S, Catacchio I, Ria R, Racanelli V, Caivano A, Solimando AG, Vergara D, Maffia M, Latorre D, Rizzello A, Zito A, Ditonno P, Maiorano E, Ribatti D, Vacca A. (2014). A HGF/cMET Autocrine Loop Is Operative in Multiple Myeloma Bone Marrow Endothelial Cells and May Represent a Novel Therapeutic Target. Clin Cancer Res. 20(22):5796-807.